Theriva Biologics shares surge 20.57% after-hours after EMA backs VCN-01 Phase 3 trial design for pancreatic cancer.

Theriva Biologics surged 20.57% in after-hours trading following the European Medicines Agency’s (EMA) endorsement of its Phase 3 trial design for VCN-01 in combination with standard chemotherapy for metastatic pancreatic ductal adenocarcinoma (PDAC). The EMA agreed with the trial’s adaptive design, repeated dosing regimen, and sample size, aligning with positive Phase 2b data showing improved survival outcomes. The company also announced plans for an End-of-Phase 2 meeting with the FDA in H1 2026 to finalize the multinational Phase 3 protocol. Theriva’s $15.5 million cash runway through Q1 2027 further supports regulatory and partnering activities, bolstering investor confidence in advancing VCN-01’s development.